Advocacy intelligence hub — real-time data for patient organizations
NeoProfen: FDA approved
For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Silvia Martini, MD
Sant'Orsola-Malpighi University Hospital, Bologna, Italy
Gary M Chan, MD
University of Utah
D Sc Lim, MD
University of Virginia
View all Premature closure of the arterial duct specialists →